Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen

Denue, Ballah Akawu; Alkali, Mohammed; Abjah, Ali Usman; Kida, Ibrahim Musa; Ajayi, Babajide O.; Fate, Bala Zira

doi:10.4137/idrt.s10044

Cited by 11 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This condition was observed despite both groups having significantly lower rates of reported previous or current experience with TB infection compared to ART-receiving individuals. Although some studies have reported lower TC levels in HIV/TB coinfection,30 studies by Adewole et al,8 Denue et al,31 and Malapati et al32 did not find significant differences in TC levels between HIV patients with TB coinfection and HIV-infected counterparts without the coinfection. Previous studies reported enhanced dyslipidemia in HIV/TB coinfection in the absence of ART, while improved lipid profile was observed in the coinfected individuals receiving NVP-based ART than in those receiving EFV-based ART 33,34.…”

Section: Discussionmentioning

confidence: 92%

Inflammation-modulating cytokine profile and lipid interaction in HIV-related risk factors for cardiovascular diseases

Gori¹,

Mduluza²,

Nyagura³

et al. 2016

TCRM

View full text Add to dashboard Cite

HIV infection and antiretroviral therapy (ART) are associated with changes in plasma levels of lipoproteins, thus posing the risk of cardiovascular complications in infected individuals. The alteration in plasma lipoprotein levels results from dysregulation of inflammation-modulating cytokines that control lipid metabolism. Little is understood regarding the relationship between the cytokines and serum lipid levels, which have been reported to be altered in adults receiving ART. The objective of this study was to describe the profiles of inflammation-modulating cytokines and their relationship to lipids as cardiovascular disease (CVD) risk factors in HIV infection. This observational cross-sectional study measured plasma levels of interleukin (IL)-10, tumor necrosis factor-alpha (TNF)-α, IL-4, total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-c) in HIV-infected and uninfected adults. A total of 219 HIV-infected participants were enrolled from an HIV treatment center; of them, 187 were receiving ART and 32 were ART naïve, while 65 were HIV-uninfected blood donors. HIV-infected individuals had higher levels of IL-10 (HIV-infected ART-naïve [P=0.0024] and ART-receiving [P=0.033]) than their uninfected counterparts. ART-naïve subjects had significantly higher plasma levels of IL-10 than ART-receiving subjects (P=0.0014). No significant difference was observed in plasma levels of IL-4 and TNF-α across the three groups. Regarding plasma lipoproteins, HDL-c levels were reduced in HIV ART-naïve (P=0.002) and ART-receiving (P=0.015) subjects compared to HIV-uninfected subjects. Similarly, TC levels were lower in the HIV-infected than in the HIV-uninfected group regardless of whether the patients were undergoing ART or not (P<0.001). IL-10 levels correlated with TC levels in the HIV-uninfected group but not in the HIV-infected groups. Levels of HDL-c were reduced, while IL-10 plasma concentrations were elevated in HIV-infected individuals. A correlation observed in HIV-uninfected individuals between anti-inflammatory cytokine IL-10 and TC was lost in HIV-infected individuals. Clinical significance of these differences needs to be ascertained with respect to HIV-related CVD risk.

show abstract

Section: Discussionmentioning

confidence: 92%

Inflammation-modulating cytokine profile and lipid interaction in HIV-related risk factors for cardiovascular diseases

Gori¹,

Mduluza²,

Nyagura³

et al. 2016

TCRM

View full text Add to dashboard Cite

show abstract

“…There were 37,110 HIV-infected patients in total, with females representing approximately 28%. Thirty-one studies (61%) were conducted in low-and middleincome countries with the highest number of studies (n = 8) reported in India [22,27,29,30,45,47,59,61], followed by six studies in Nigeria [24,31,34,36,50,54], and four studies each in Brazil [23,32,41,44], Norway [15,16,55,62], and USA [17,39,40,53]. Nonetheless, studies conducted in high-income countries were generally larger in size (n = 30,120 participants), compared with studies conducted in low-and middleincome countries (n = 7488).…”

Section: Resultsmentioning

confidence: 98%

Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: A systematic review and meta-analysis

Nduka

Sarki

Uthman

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…3,[24][25][26] Chronic HIV infection and treatment with ARVs are both associated with dyslipidemia, and cardiovascular risk is often modulated by the administration of LDL-lowering statin therapy. 1,2,4,27,28 Interestingly, the phenotypes of low LDL associated with HCV and hypercholesterolemia associated with HIV are often attenuated in the setting of HIV/HCV coinfection. [5][6][7][8]10 Treatment of chronic HCV infection is now possible with interferon (IFN)-free regimens composed of directly acting antiviral (DAA) agents that directly inhibit viral proteins.…”

Section: Introductionmentioning

confidence: 99%

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration

Townsend

Meissner

Sidharthan

et al. 2016

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is associated with lower serum concentration of low-density lipoprotein (LDL-C), the primary cholesterol metabolite targeted pharmaceutically to modulate cardiovascular risk. Chronic infection with human immunodeficiency virus (HIV) and treatment with antiretrovirals (ARVs) are associated with dyslipidemia and increased risk of cardiovascular disease. In subjects coinfected with HIV and HCV, lipid abnormalities associated with either infection alone are often attenuated. Treatment of chronic HCV infection in HIV/HCV-coinfected subjects is now possible with interferon (IFN)-free regimens composed of directly acting antivirals (DAAs). We previously observed a marked increase in serum LDL-C in HCVmonoinfected subjects treated with sofosbuvir and ribavirin (SOF/RBV) that correlated with viral decline in serum, suggesting a direct influence of HCV clearance on serum cholesterol. In the present study, we assessed longitudinal changes in cholesterol in HIV/HCV-coinfected subjects during treatment of HCV genotype-1 (GT1) infection with combination DAA therapy. We report a rapid increase in LDL-C and LDL particle size by week 2 of treatment that was sustained during and after treatment in HIV/HCV-coinfected subjects. No change in serum LDL-C was observed at day 3 of treatment, in spite of a marked reduction in serum HCV viral load, suggesting LDL-C increases do not directly reflect HCV clearance as measured in peripheral blood. After effective DAA therapy for HCV, an increase in LDL should be anticipated in HIV/HCV-coinfected subjects.

show abstract

Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen

Cited by 11 publications

References 38 publications

Inflammation-modulating cytokine profile and lipid interaction in HIV-related risk factors for cardiovascular diseases

Inflammation-modulating cytokine profile and lipid interaction in HIV-related risk factors for cardiovascular diseases

Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: A systematic review and meta-analysis

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration

Contact Info

Product

Resources

About